
Please try another search
Oppenheimer analysts initiated research coverage of GE HealthCare (NASDAQ:GEHC) with a Buy rating and a $97 per share price target.
The target implies an upside potential of about 30% relative to yesterday’s closing price.
GE HealthCare, which was spun off by General Electric (NYSE:GE) earlier this year, is described as “the global leader in healthcare diagnostics, imaging, and intervention.”
“GE's unparalleled depth and breadth of products in X-rays, CT, MRI, ultrasound, services, and digital solutions provide a unique ecosystem allowing multiple touch points along the continuum of care. Following its recent spin-out from the parent company, a more focused GE has emerged with a strategic outlook of a 4-6% revenue CAGR, adjusted EBIT margins of high-teens to twenty percent, and FCF generation of 85%+,” analysts said in a client note.
Hence, analysts are positive on GEHC shares as the company operates in attractive markets while being financially disciplined.
GEHC shares are up 0.5% in pre-market Tuesday.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.